Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,690 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risk factor profiles based on estimated glomerular filtration rate and dipstick proteinuria among participants of the Specific Health Check and Guidance System in Japan 2008.
Iseki K, Asahi K, Moriyama T, Yamagata K, Tsuruya K, Yoshida H, Fujimoto S, Konta T, Kurahashi I, Ohashi Y, Watanabe T. Iseki K, et al. Among authors: fujimoto s. Clin Exp Nephrol. 2012 Apr;16(2):244-9. doi: 10.1007/s10157-011-0551-9. Epub 2011 Nov 8. Clin Exp Nephrol. 2012. PMID: 22057582
Prevalence of chronic kidney disease in the Japanese general population.
Imai E, Horio M, Watanabe T, Iseki K, Yamagata K, Hara S, Ura N, Kiyohara Y, Moriyama T, Ando Y, Fujimoto S, Konta T, Yokoyama H, Makino H, Hishida A, Matsuo S. Imai E, et al. Among authors: fujimoto s. Clin Exp Nephrol. 2009 Dec;13(6):621-30. doi: 10.1007/s10157-009-0199-x. Epub 2009 Jun 11. Clin Exp Nephrol. 2009. PMID: 19513802
Underestimating chronic kidney disease by urine dipstick without serum creatinine as a screening tool in the general Japanese population.
Uchida D, Kawarazaki H, Shibagaki Y, Yasuda T, Tominaga N, Watanabe T, Asahi K, Iseki K, Iseki C, Tsuruya K, Yamagata K, Moriyama T, Narita I, Fujimoto S, Konta T, Kondo M, Kasahara M, Kimura K. Uchida D, et al. Among authors: fujimoto s. Clin Exp Nephrol. 2015 Jun;19(3):474-80. doi: 10.1007/s10157-014-1019-5. Epub 2014 Aug 24. Clin Exp Nephrol. 2015. PMID: 25150509
Targeted proteomics reveals promising biomarkers of disease activity and organ involvement in antineutrophil cytoplasmic antibody-associated vasculitis.
Ishizaki J, Takemori A, Suemori K, Matsumoto T, Akita Y, Sada KE, Yuzawa Y, Amano K, Takasaki Y, Harigai M, Arimura Y, Makino H, Yasukawa M, Takemori N, Hasegawa H; Research Committee of Intractable Vasculitis Syndrome and the Research Committee of Intractable Renal Disease of the Ministry of Health, Labour and Welfare of Japan. Ishizaki J, et al. Arthritis Res Ther. 2017 Sep 29;19(1):218. doi: 10.1186/s13075-017-1429-3. Arthritis Res Ther. 2017. PMID: 28962592 Free PMC article.
Rationale and study design of a clinical trial to assess the effects of LDL apheresis on proteinuria in diabetic patients with severe proteinuria and dyslipidemia.
Wada T, Muso E, Maruyama S, Hara A, Furuichi K, Yoshimura K, Miyazaki M, Sato E, Abe M, Shibagaki Y, Narita I, Yokoyama H, Mori N, Yuzawa Y, Matsubara T, Tsukamoto T, Wada J, Ito T, Masutani K, Tsuruya K, Fujimoto S, Tsuda A, Suzuki H, Kasuno K, Terada Y, Nakata T, Iino N, Kobayashi S. Wada T, et al. Among authors: fujimoto s. Clin Exp Nephrol. 2018 Jun;22(3):591-596. doi: 10.1007/s10157-017-1488-4. Epub 2017 Oct 27. Clin Exp Nephrol. 2018. PMID: 29080119 Clinical Trial.
Usefulness of tissue inhibitor of metalloproteinase 1 as a predictor of sustained remission in patients with antineutrophil cytoplasmic antibody-associated vasculitis.
Ishizaki J, Takemori A, Horie K, Hiraoka D, Suemori K, Matsumoto T, Sada KE, Amano K, Harigai M, Arimura Y, Makino H, Takenaka K, Takemori N, Hasegawa H; Research Committee of Intractable Vasculitis Syndrome and the Research Committee of Intractable Renal Disease of the Ministry of Health, Labour and Welfare of Japan. Ishizaki J, et al. Arthritis Res Ther. 2021 Mar 20;23(1):91. doi: 10.1186/s13075-021-02471-5. Arthritis Res Ther. 2021. PMID: 33743769 Free PMC article.
Favorable therapeutic efficacy of low-density lipoprotein apheresis for nephrotic syndrome with impaired renal function.
Muso E, Sakai S, Ogura Y, Yukawa S, Nishizawa Y, Yorioka N, Saito T, Mune M, Sugiyama S, Iino Y, Hirano T, Hattori M, Watanabe T, Yokoyama H, Sato H, Uchida S, Wada T, Shoji T, Oda H, Mori K, Kimura H, Ito O, Nishiyama A, Maruyama S, Inagi R, Fujimoto S, Tsukamoto T, Suzuki Y, Honda H, Babazono T, Tsuruya K, Yuzawa Y. Muso E, et al. Among authors: fujimoto s. Ther Apher Dial. 2022 Feb;26(1):220-228. doi: 10.1111/1744-9987.13694. Epub 2021 Jun 21. Ther Apher Dial. 2022. PMID: 34057286 Free PMC article.
Relationship between the lower limit of systolic blood pressure target and kidney function decline in advanced chronic kidney disease: an instrumental variable analysis from the REACH-J CKD cohort study.
Kurasawa S, Yasuda Y, Kato S, Maruyama S, Okada H, Kashihara N, Narita I, Wada T, Yamagata K; REACH-J CKD collaborators. Kurasawa S, et al. Hypertens Res. 2023 Nov;46(11):2478-2487. doi: 10.1038/s41440-023-01358-z. Epub 2023 Jul 18. Hypertens Res. 2023. PMID: 37460823
A digest from evidence-based clinical practice guideline for IgA nephropathy 2020.
Suzuki H, Kikuchi M, Koike K, Komatsu H, Matsuzaki K, Takahashi K, Ichikawa D, Okabe M, Obata Y, Katafuchi R, Kihara M, Kohatsu K, Sasaki T, Shimizu A, Nakanishi K, Fukuda A, Miyazaki Y, Muto M, Yanagawa H, Suzuki Y, Fujimoto S, Furuichi K, Okada H, Narita I; Committee of Clinical Practical Guideline for IgA Nephropathy 2020. Suzuki H, et al. Among authors: fujimoto s. Clin Exp Nephrol. 2021 Dec;25(12):1269-1276. doi: 10.1007/s10157-021-02095-8. Epub 2021 Sep 26. Clin Exp Nephrol. 2021. PMID: 34564790 No abstract available.
2,690 results